AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Here are three fantastic biotech stocks harnessing the power of AI that could make a great addition to your portfolio. The ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...